BD1:
Three Great Announcements in Three Days:
Today:
POSITIVE RESULTS FROM EVALUATION OF EXO-NET IN PANCREATIC CANCER
• Pancreatic cancer is one of the most deadly cancers, with a 5-year survival rate of 10%
• No liquid biopsy tests exist for the early detection of pancreatic cancer
• Positive results from collaborative research study to evaluate BARD1’s EXO-NET™
exosome capture technology and Minomic’s anti-GPC-1 antibody for detection of pancreatic cancer
• EXO-NET™ was shown to isolate exosomes from pancreatic cancer patients and healthy control plasma samples
• Minomic’s GPC-1 antibody was shown to specifically bind EXO-NET isolated pancreatic cancer exosomes and not bind healthy (non-cancer) exosomes
• Pilot study demonstrates the scientific feasibility of utilising EXO-NET™ to isolate exosomes for pancreatic cancer detection in conjunction with an anti-GPC-1 antibody
Yesterday:
• Australian Patent No. 2015218188 granted to BARD1 by IP Australia
• Provides patent protection for hTERT in Australia until 2035
Melbourne, Australia, 15 March 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or Company) announces that it has been granted Australian patent number 2015218188 entitled ‘Method of Detecting Cancer’. Australian patent 2015218188 covers the use of the Company’s hTERT antibody to resolve inconclusive cytology and detect malignant cells.
Friday:
• BARD1 gains Class II IVD device registration for hTERT from South Korea’s Ministry of Food and Drug Safety
• BARD1’s exclusive Korean distributor Mirax places first hTERT product order Melbourne, Australia, 12 March 2021:
BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that it has gained Class II In-Vitro Diagnostic (IVD) medical device registration from South Korea’s Ministry of Food and Drug Safety (MFDS) for the Company’s hTERT test, which is used as an adjunct to urine cytology testing.
US Co. Grail recently sold for $8 000 000 000 USD,
Which was also in the early detection of cancer space....
